Modulatory effects of extract of Heinsia crinita against fructose/streptozotocin-induced oxidative stress in diabetic rat models.

Oxidative stress plays a crucial role in the development of type 2 diabetes and the associated microvascular and cardiovascular complications. In the study, we have investigated the effects of Heinsia crinita (H. crinita) extracts on lipid peroxidation and oxidative stress responses using diabetic rats. Type 2 diabetes was induced with 10 % fructose/40 mg/kg body weight streptozotocin (STZ). H. crinita extract was administered at 200 and 400 mg/kg body weight twice daily for 21 days, in addition to metformin (MET: 500 mg/kg body weight) control. Molecular docking analysis was performed to determine the binding affinity of H. crinita extracts to the DNA binding domains of peroxisome proliferator-activated receptor (Ppar) and retinoid x receptor (Rxr) protein crystal structures, showing different binding affinities for putative active compounds from the plant. Fasting blood glucose (FBG), body and organ weight changes were determined showing that H. crinita extract induced an anti-hyperglycemic effect in the treated animals, with changes (either decrease or increase) in liver and kidney weights. A decrease in mRNA expression of peroxisome proliferator-activated receptors (ppar), sterol regulatory element-binding protein 1 (srebp-1c), liver x-receptor (lxr), retinoid x receptors (rxr), cytochrome p45041 (cyp4a1) and acyl-CoA oxidase (acox1) in diabetic animals were observed, compared to the control. A dose-specific decrease or increase in antioxidant enzymes (superoxide dismutase: SOD, catalase: CAT, reduced glutathione: GSH, glutathione peroxidase: GPx) transcripts and activity levels were also observed. We also observed exposure-specific decrease or increase of malondialdehyde (MDA) levels. Our data suggested that H. crinita extract possesses protective effects against diabetes-induced oxidative stress. These effects might be attributed to their binding and activation of nuclear receptors, indicating their cellular mode of action that is comparable to MET.

Artemisia annua as a possible contraceptive agent: a clue from mammalian rat model.

In a previous study, we evaluated the maternal and fetal safety of antimalarial herb Artemisia annua with artemisinin yield of 1.09%. Here, we attempted to ascertain the contraceptive claim of A. annua. Sexually matured female Wistar rats (180-220 g) were allotted into four study groups of six rats each. The control group received normal saline, while the A. annua-treated groups received 100, 200 and 300 mg/kg of A. annua for 2 weeks, followed by mating with proven fertile males (1:1). The rats were allowed to carry the pregnancy to term. At birth and weaning periods, selected reproductive outcome and fertility indices were determined. The results showed that A. annua significantly reduced litter size, reproductive outcome and fertility indices compared with the control (p <  0.05). These results imply that A. annua could serve as a prospective contraceptive agent in addition to its antimalarial activity.

Biochemical and haematological evaluation of repeated dose exposure of male Wistar rats to an ethanolic extract of Artemisia annua.

Artemisia annua is widely used for the treatment of malaria and other disorders. In a previous study, the artemisinin concentration in the dry leaves of A. annua grown under humid tropical conditions was determined to be 1.098% using reversed phase high performance liquid chromatography. In the current study, biochemical and haematological evaluations of ethanolic leaf extracts derived from such plants (EAA) were carried out in 20 male Wistar rats. Rats were divided into four study groups of saline-treated (control) and test groups exposed orally to graded doses of EAA for 28 days. The results showed that the liver function and haematological indices, and testosterone levels were not adversely affected. High density lipoprotein -cholesterol was reduced at 100 mg/kg of EAA, atherogenic index as well as low density lipoprotein -cholesterol was raised, and glucose concentration was reduced significantly at the 100 and 200 mg/kg of EAA (p < 0.05). In addition to serving as a possible antidiabetic agent, EAA may not predispose users to hepatotoxicity, haematotoxicity and testicular toxicity. However, due to the possible risk of atherosclerosis, we advise that the plant extract should be taken with caution in people with atherosclerotic condition.

A safety assessment of the antimalarial herb Artemisia annua during pregnancy in Wistar rats.

Artemisia annua is a Chinese antimalarial herb that has been used for more than 2000 years. The maternal and foetal safety of the ethanolic leaf extract of therapeutically active Artemisia annua (EAA), with previously determined artemisinin yield of 1.098% was evaluated in Wistar rats. Twenty pregnant rats, divided into four study groups of saline treated (control), and test groups administered orally with 100, 200 and 300 mg/kg body weights of EAA, respectively, from gestation days (GD) 8 to 19. Following overnight fast, animals were sacrificed on GD 20, and maternal blood was collected to evaluate biochemical and haematological markers. Foetuses were carefully removed, weighed, and observed for any possible malformation. Biochemical and haematological studies revealed that EAA did not result in maternal hepatotoxicity, haematotoxicity, and hyperlipidemia. While litter size significantly decreased (p < 0.05) at 100 mg/kg EAA, maternal estrogen levels decreased in all the EAA-treated groups. Non-viable (21%) and malformed (31%) foetuses were observed at the 300 mg/kg dose of EAA, which implies that although consumption of the leaf extract may not predispose users to hepatotoxicity, haematotoxicity, and hyperlipidemia, it should be taken with caution during pregnancy due to possible risk of embryotoxicity at concentrations higher than the therapeutic dose.